Glioblastoma Therapy in the Age of Molecular Medicine

Luiz Henrique Medeiros Geraldo*, Celina Garcia, Anna Carolina Carvalho da Fonseca, Luiz Gustavo Feijo Dubois, Tania Cristina Leite de Sampaio e Spohr, Diana Matias, Eduardo Sabino de Camargo Magalhaes, Rackele Ferreira do Amaral, Barbara Gomes da Rosa, Izabella Grimaldi, Felipe Sceanu Leser, Jose Marcos Janeiro, Lucy Macharia, Caroline Wanjiru, Claudia Maria Pereira, Vivaldo Moura-Neto, Catarina Freitas, Flavia Regina Souza Lima*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

69 Citations (Scopus)

Abstract

Glioblastoma (GBM) is the most common and fatal primary malignant brain tumor. Despite advances in the understanding of the biology of gliomas, little has changed in the treatment of these tumors in the past decade. Phase III clinical trials showed no benefit for the use of bevacizumab in newly diagnosed patients, leading to a renewed search for new antiangiogenic drugs, as well as immunotherapeutic approaches, including checkpoint inhibitors, chimeric antigen receptor T cells, and intracerebral CpG-oligodeoxynucleotides. The emerging role of infiltrating microglia and macrophages, and of metabolic alterations, is also being taken into account in preclinical research and drug development. In this review, we discuss progress in the search for new therapeutic strategies, particularly approaches focusing on the tumor microenvironment.

Original languageEnglish
Pages (from-to)46-65
Number of pages20
JournalTrends in cancer
Volume5
Issue number1
DOIs
Publication statusPublished - Jan-2019
Externally publishedYes

Keywords

  • EPIDERMAL-GROWTH-FACTOR
  • CANCER STEM-CELLS
  • NEWLY-DIAGNOSED GLIOBLASTOMA
  • CENTRAL-NERVOUS-SYSTEM
  • PHASE-II TRIAL
  • FACTOR RECEPTOR
  • T-CELLS
  • RECURRENT GLIOBLASTOMA
  • HUMAN GLIOMA
  • TUMOR-CELL

Cite this